← All earnings call summaries
Orchid Pharma Limited — Q1FY27 Earnings Call Summary
Key Takeaways
- Industry pricing pressure persists; better demand expected in H2 FY27, especially in regulated markets
- Capex for FY27 mainly INR750 Cr for 7-ACA and USD20-25 million for cefiderocol project
- Q1 FY27 revenue grew 15% y-y to INR304 Cr; EBITDA improved to INR25 Cr from INR10 Cr in Q1 FY26
- FY26 combined revenue INR1,233 Cr vs INR1,398 Cr in FY25; gross margin declined to 32% from 36%
- AMS division EBITDA loss reduced to INR0.5 Cr in Q1 FY27; revenue INR5 Cr
- Cefiderocol facility commissioning by Dec 2026; product approval expected Q3 FY28 subject to DCGI trial waiver
- Long-term growth driven by combined Orchid-Dhanuka platform, backward integration, and new product launches
- Multiple analyst queries on 7-ACA ramp-up and market pricing; management expects stable prices and focus on efficiency
- 7-ACA plant commissioning targeted by March 2027; ramp-up to 80-100% utilization within first year
- Exblifep volumes growing steadily in Europe; licensing value in Russia approx. USD178 million over 10 years
📄 Source: View original transcript (PDF)
Get Orchid Pharma Limited earnings summaries on Telegram
Add Orchid Pharma Limited to your watchlist. Receive AI-generated summaries within hours of every earnings call.
Start free →
Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.